Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of TIL in Advanced Solid Tumors (DFGD)
Sponsor: Shanghai Juncell Therapeutics
Summary
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Official title: A Study Study of Tumor Infiltrating Lymphocytes Injection (GC101/203 TIL) in Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-04-01
Completion Date
2027-06-30
Last Updated
2025-12-16
Healthy Volunteers
No
Conditions
Interventions
GC203 TIL(gene-edited TIL) or autologous TILs
the candidates will be assigned to GC203 TIL(gene-edited TIL) group or autologous TILs group according the volume of TIL sample
Locations (1)
Third Affiliated Hospital of Naval Medical University
Shanghai, China